MA53543A - Vaccins peptidiques - Google Patents

Vaccins peptidiques

Info

Publication number
MA53543A
MA53543A MA053543A MA53543A MA53543A MA 53543 A MA53543 A MA 53543A MA 053543 A MA053543 A MA 053543A MA 53543 A MA53543 A MA 53543A MA 53543 A MA53543 A MA 53543A
Authority
MA
Morocco
Prior art keywords
peptide vaccines
vaccines
peptide
Prior art date
Application number
MA053543A
Other languages
English (en)
Inventor
Zsolt Csiszovszk
Julianna Liszewicz
Orsolya Lorincz
Mónika Megyesi
Levente Molnar
Katalin Pantya
Eszter Somogyi
Eniko Toke
József Toth
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1814367.7A external-priority patent/GB201814367D0/en
Priority claimed from GBGB1814365.1A external-priority patent/GB201814365D0/en
Priority claimed from GBGB1814366.9A external-priority patent/GB201814366D0/en
Priority claimed from GBGB1814364.4A external-priority patent/GB201814364D0/en
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MA53543A publication Critical patent/MA53543A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
MA053543A 2018-09-04 2019-09-03 Vaccins peptidiques MA53543A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1814367.7A GB201814367D0 (en) 2018-09-04 2018-09-04 Peptide Vaccines
GBGB1814365.1A GB201814365D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814366.9A GB201814366D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814364.4A GB201814364D0 (en) 2018-09-04 2018-09-04 Peptide vaccines

Publications (1)

Publication Number Publication Date
MA53543A true MA53543A (fr) 2021-07-14

Family

ID=67874441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053543A MA53543A (fr) 2018-09-04 2019-09-03 Vaccins peptidiques

Country Status (15)

Country Link
US (2) US11666644B2 (fr)
EP (1) EP3846845A1 (fr)
JP (2) JP2021536487A (fr)
KR (1) KR20210086612A (fr)
CN (1) CN113329761A (fr)
AU (1) AU2019334437A1 (fr)
BR (1) BR112021004071A2 (fr)
CA (1) CA3110760A1 (fr)
CL (1) CL2021000532A1 (fr)
CO (1) CO2021004019A2 (fr)
IL (1) IL281224A (fr)
MA (1) MA53543A (fr)
MX (1) MX2021002449A (fr)
SG (1) SG11202101888YA (fr)
WO (1) WO2020048990A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110651189A (zh) 2017-03-03 2020-01-03 特雷斯生物公司 肽疫苗
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
JP2024518378A (ja) 2021-05-05 2024-05-01 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
BR9708161A (pt) 1996-03-11 1999-07-27 Epimmune Inc Peptídeos com aumentada afinidade de ligação para moléculas hla
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
EP0970126B1 (fr) 1997-04-14 2001-04-18 Micromet AG Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
CA2323514A1 (fr) 1998-04-01 1999-10-07 Yale University Methode de modulation selective des interactions entre survivine et tubuline
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1235841A4 (fr) * 1999-12-10 2006-04-12 Epimmune Inc Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
WO2005049073A2 (fr) 2003-11-19 2005-06-02 Survac Aps Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer
CN101434647A (zh) 2004-01-20 2009-05-20 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
WO2005118626A2 (fr) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
US8487076B1 (en) 2005-01-25 2013-07-16 Nec Corporation HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
CN103169958A (zh) 2005-02-04 2013-06-26 萨瓦克公司 存活蛋白肽疫苗
CN100402554C (zh) 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
CN101437542A (zh) 2006-03-01 2009-05-20 詹森药业有限公司 联合淋巴细胞清除剂与ctl及细胞因子的癌症治疗
WO2008035350A1 (fr) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Vaccins à multiples épitopes spécifiques à un antigène
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8124408B2 (en) 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2042600A1 (fr) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications
CN101981187A (zh) 2008-03-31 2011-02-23 株式会社生物免疫平衡 MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (fr) 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
US20120244145A1 (en) 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (fr) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
WO2012126118A1 (fr) 2011-03-21 2012-09-27 Atlantic Cancer Research Institute Polypeptides présentant une affinité pour les protéines de choc thermique (hsp) et complexes associés à une hsp (hacs) et leur utilisation en diagnostic et en thérapie
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
US20140234350A1 (en) 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods
CN111905099A (zh) 2013-03-27 2020-11-10 免疫疫苗技术有限公司 用于改善存活蛋白疫苗在癌症治疗中的功效的方法
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015143335A1 (fr) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Méthodes et compositions pour protéines spike de coronavirus chimère
EP3134104B1 (fr) 2014-04-25 2018-12-26 Tria Bioscience Corp. Compositions de support d'haptène synthétique et procédés
CA2961179A1 (fr) 2014-09-14 2016-03-17 Washington University Vaccins anticancereux personnalises, et procedes correspondants
US20160074489A1 (en) 2014-09-15 2016-03-17 Regen Biopharma, Inc Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
WO2016090177A1 (fr) * 2014-12-03 2016-06-09 Verik Bio, Inc. Identification, sélection et utilisation d'épitopes de cellule t à haut potentiel curatif
EP3242883A4 (fr) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Mimétiques de lipide a, procédés de préparation, et leurs utilisations
JP7236216B2 (ja) 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US20180162913A1 (en) 2015-05-01 2018-06-14 Immunovaccine Technologies Inc. Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
US11191820B2 (en) * 2015-06-29 2021-12-07 Ose Immunotherapeutics Method for inducing early T memory response with short peptides anti-tumor vaccine
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US9790562B2 (en) 2015-09-30 2017-10-17 Augusta University Research Institute, Inc. Compositions and methods for the detection or treatment of uterine leiomyosarcoma
JP2018532736A (ja) 2015-10-12 2018-11-08 ナントミクス，エルエルシー チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
WO2017083963A1 (fr) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Systèmes adjuvant et compositions vaccinales sans eau comprenant un adjuvant de type polyi:c et un adjuvant lipidique
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
CA3023560A1 (fr) 2016-05-13 2017-11-16 Mbl International Corp. Systeme et procede d'echange de peptides
JP2020503840A (ja) * 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3369431A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Vaccin
CN110651189A (zh) 2017-03-03 2020-01-03 特雷斯生物公司 肽疫苗
EP3370065A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Peptides immunogènes
US20200230057A1 (en) 2017-07-10 2020-07-23 Immunovaccine Technologies Inc. Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof
US20210177955A1 (en) 2017-11-08 2021-06-17 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
JP7103726B2 (ja) 2017-11-09 2022-07-20 イミューノヴァクシーン テクノロジーズ インコーポレイテッド 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用
WO2019133853A1 (fr) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Protéines se liant à l'antigène ciblant des antigènes partagés
US20210213066A1 (en) 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
EP3796923A4 (fr) 2018-05-18 2022-03-09 Children's National Medical Center Thérapie ciblée améliorée par lymphocytes t
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
AU2019383785A1 (en) 2018-11-19 2021-06-03 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2020146434A2 (fr) 2019-01-07 2020-07-16 Children's National Medical Center Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation
EP3908292A4 (fr) 2019-01-07 2023-01-04 Children's National Medical Center Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple
CA3153179A1 (fr) 2019-10-16 2021-04-22 Immunovaccine Technologies Inc. Formulations d'emulsion a phase continue aqueuse pour l'administration d'agents actifs ou therapeutiques
CN110713546B (zh) 2019-10-31 2021-04-20 中国医科大学附属第一医院 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
CL2021000532A1 (es) 2021-09-24
CO2021004019A2 (es) 2021-07-19
JP2021536487A (ja) 2021-12-27
JP2024097033A (ja) 2024-07-17
US20230102031A1 (en) 2023-03-30
IL281224A (en) 2021-04-29
WO2020048990A1 (fr) 2020-03-12
US11666644B2 (en) 2023-06-06
SG11202101888YA (en) 2021-03-30
KR20210086612A (ko) 2021-07-08
EP3846845A1 (fr) 2021-07-14
CA3110760A1 (fr) 2020-03-12
CN113329761A (zh) 2021-08-31
US20240000911A1 (en) 2024-01-04
BR112021004071A2 (pt) 2021-06-01
MX2021002449A (es) 2021-08-05
AU2019334437A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MA47677A (fr) Vaccins peptidiques
MA46766A (fr) Vaccin antigrippal
MA46584A (fr) Vaccin contre le cytomégalovirus humain
DK3393505T3 (da) Rekombinante zika-vacciner
DK3393510T3 (da) Zikavirusvaccine
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
MA46255A (fr) Vaccins anticancéreux
MA46316A (fr) Vaccin contre le cytomégalovirus humain
DK3723783T3 (da) Mitokondrie-målrettede peptider
MA46378A (fr) Vaccins hpv16 thérapeutiques
DK3558351T3 (da) Kombinationsvaccine til svin
DK3548058T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
MA52011A (fr) Vaccins peptidiques contre l'interleukine-31
DK3840767T3 (da) Peptider
IL281224A (en) Peptide compounds
DK3244920T3 (da) Mund- og klovsyge-vaccine
DK3274447T3 (da) Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
DK3590523T3 (da) Vækstfremmende peptider og anvendelser deraf
IL278830A (en) Reverse peptide vaccine
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
MA52180A (fr) Vaccins thérapeutiques anti-abêta
DK3178838T3 (da) Koc1-afledt peptid og vaccine, der indbefatter dette
DK3630793T3 (da) Rekombinant protein
DK3405212T3 (da) Cancervacciner
MA52588A (fr) Macrocyclase peptidique